Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Current application status and structure–activity relationship of selective and non-selective JAK inhibitors in diseases

19 Jul 2023

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytokine Signaling Pathways and Interactions
Share to Pharmacological Effects of Natural Compounds
Share to Rheumatoid Arthritis Research and Therapies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37478665
DOI: 10.1016/j.intimp.2023.110660

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Current application status and structure–activity relationship of selective and non-selective JAK inhibitors in diseasesPMID 37478665Read ↗

Insight into Janus kinases specificity: From molecular architecture to cancer therapeuticsSemantic proximity Read ↗

JAK Kinases in Health and Disease: An UpdateSemantic proximity Read ↗

JAK inhibitors ∼ overview∼Semantic proximity Read ↗

Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseasesSemantic proximity Read ↗

JAK3 inhibitors for the treatment of inflammatory and autoimmune diseases: a patent review (2016–present)Semantic proximity Read ↗

A STAT inhibitor patent review: progress since 2011Semantic proximity Read ↗

Upadacitinib: Mechanism of action, clinical, and translational scienceSemantic proximity Read ↗

Integrated Ligand and Structure based approaches towards developing novel Janus Kinase 2 inhibitors for the treatment of myeloproliferative neoplasmsSemantic proximity Read ↗

Polypharmacology is an enduring and nearly universal property of kinase inhibitorsSemantic proximity Read ↗

A structure-function perspective of Jak2 mutations and implications for alternate drug design strategies: the road not taken.Semantic proximity Read ↗

The many faces of Janus kinase.Semantic proximity Read ↗

Drug-repurposing against COVID-19 by targeting a key signaling pathway: An in silico studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.